leading glp-1 treatments for diabetes 2025 Impact: How GLP-1s Are Changing the Treatment Paradigm The expanding landscape of GLP-1

Patients with autoimmune hypothyroidism who have appropriate indications such as type 2 diabetes or obesity may safely use these medications under medical supervision, provided they do not have a personal or family history of medullary thyroid carcinoma or MEN 2 syndrome

In Obesity in Europe 1993 (eds Ditschuneit, H

For weight management, lifestyle interventions, nutritional counseling, or alternative pharmacologic options may be considered based on individual risk-benefit assessment

Patients with type 2 diabetes mellitus (T2DM) have a 1.31.5-fold increased risk of CRC compared with non-diabetic individuals, attributed to hyperinsulinemia, chronic inflammation, and altered gut microbiome [2, 3]